Infectious Disease Clinical Trial Award: Optimising Interventions for Impact
Funds RCTs led from Africa or Asia to optimize licensed interventions for infectious diseases, generating evidence to inform policy and improve health outcomes in low- and middle-income countries.
Funder: Wellcome Trust
Due Dates: June 2, 2026 (Full application, 15:00 BST)
Funding Amounts: £1,000,000–£8,000,000 per award | 3–5 years duration | 8–12 awards expected
Summary: Supports randomized controlled trials led from Africa or Asia to optimize licensed interventions for infectious diseases, generating evidence to inform policy and improve outcomes in low- and middle-income countries.
Key Information: Lead applicant and at least one coapplicant must be based in Africa, South Asia, or South-East Asia; focus must be on specific infectious diseases and interventions.
Description
This funding opportunity supports transdisciplinary research teams led from Africa, South Asia, or South-East Asia to conduct high-quality randomized controlled trials (RCTs) aimed at optimizing licensed pharmaceutical interventions—such as vaccines or therapeutics—for infectious diseases. The targeted diseases include mycobacterial, bacterial, invasive fungal infections, dengue, leishmaniasis, or schistosomiasis. The overarching goal is to generate robust, policy-relevant evidence that can drive changes in clinical guidelines, policy, and practice, leading to measurable improvements in treatment and prevention among communities most affected in low- and middle-income countries (LMICs). Proposals must be contextually relevant, engage stakeholders, build local capacity, and prioritize equitable access and real-world impact.
